



## Half-yearly report on the liquidity contract with Gilbert Dupont

Market: Euronext Paris  
ISIN code / Mnemo: CH0308403085 / GNRO  
Web site: [www.geneuro.com](http://www.geneuro.com)

Pursuant to the liquidity contract entrusted by GENEURO SA to Gilbert Dupont, as of June 30, 2019, the following assets appeared on the liquidity account:

- Number of shares: 76,734
- Cash balance of the liquidity account: € 126,442.04

During the first half of 2019, the following shares were traded:

PURCHASES	52,379 shares	197,649.65 €	480 transactions
SALES	42,152 shares	159,302.35 €	397 transactions

As a reminder, as of December 31, 2018, the following resources were booked to the liquidity account:

- Number of shares: 66,507
- Cash balance of the liquidity account: € 164,789.34

### About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis or Type 1 Diabetes, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 28 employees and rights to 16 patent families protecting its technology.

For more information, visit: [www.geneuro.com](http://www.geneuro.com)

### Contacts

#### GeNeuro

Jesús Martin-Garcia  
Chairman and CEO  
+41 22 552 4800  
[investors@geneuro.com](mailto:investors@geneuro.com)

#### NewCap (France)

Mathilde Bohin (investors)  
+33 1 44 71 98 52  
Nicolas Merigeau (media)  
+33 1 44 71 94 98  
[geneuro@newcap.eu](mailto:geneuro@newcap.eu)

#### Halsin Partners

Mike Sinclair (media)  
+44 20 7318 2955  
[msinclair@halsin.com](mailto:msinclair@halsin.com)

#### LifeSci Advisors

Chris Maggos (investors)  
+1 646 597 6970  
+41 79 367 6254  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)